Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Aprepitant
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Oxilio
Deal Size : Undisclosed
Deal Type : Agreement
Details : Quotient has prior experience of working with the Nuformix NXP-001 co-crystal and previously developed a capsule and a powder for oral suspension formulation of Aprepitant, evaluating its performance in a relative bioavailability study versus EMEND.
Product Name : NXP-001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 02, 2022
Lead Product(s) : Aprepitant
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Oxilio
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Aprepitant
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial
Details : HT-001 (aprepitant) is a proprietary, non-steroidal topical formulation, which is being evaluated for the treatment of pruritus associated skin toxicities.
Product Name : HT-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 15, 2025
Lead Product(s) : Aprepitant
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aprepitant
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hoth Plans Expanded Access Application for HT-001 in Cancer Patients
Details : HT-001 (aprepitant) is an investigational topical therapeutic product. which is being evaluated for the treatment of rash and skin disorders associated with EGFR inhibitor therapy.
Product Name : HT-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 10, 2025
Lead Product(s) : Aprepitant
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aprepitant
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hoth Therapeutics Achieves Breakthrough in Phase 2a Cancer Treatment Trial
Details : HT-001 (aprepitant) is an investigational topical therapeutic product. which is being evaluated for the treatment of rash and skin disorders associated with EGFR inhibitor therapy.
Product Name : HT-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 07, 2025
Lead Product(s) : Aprepitant
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aprepitant
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : PlusVitech
Deal Size : Undisclosed
Deal Type : Collaboration
Nanoform and PlusVitech Partner to Repurpose Aprepitant as a Treatment for Lung Cancer
Details : Under the collaboration, PlusVitech will use Nanoform's state-of-the-art nanomedicine technology to repurpose the anti-nausea medicine aprepitant as a treatment for non-small cell lung cancer.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 04, 2024
Lead Product(s) : Aprepitant
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : PlusVitech
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Aprepitant
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hoth Therapeutics Reports Positive Data on HT-001 for EGFRI-Associated Skin Toxicities
Details : HT-001 (aprepitant) is an investigational topical therapeutic product. which is being evaluated for the treatment of rash and skin disorders associated with EGFR inhibitor therapy.
Product Name : HT-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 09, 2024
Lead Product(s) : Aprepitant
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aprepitant
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial
Details : HT-001 (aprepitant) is an investigational topical therapeutic product, being evaluated for the treatment of rash and skin disorders associated with EGFR inhibitor therapy.
Product Name : HT-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 09, 2024
Lead Product(s) : Aprepitant
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aprepitant
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hoth Therapeutics Receives FDA Approval to Expand HT-001 Trial for Severely Ill Patients
Details : HT-001 (aprepitant) is a Neurokinin 1 receptor inhibitor. It is being evaluated in phase 2 clinical trials for the treatment of skin toxicities associated with EGFR Inhibitors.
Product Name : HT-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 18, 2024
Lead Product(s) : Aprepitant
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aprepitant
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HT-001 (aprepitant) is an investigational topical therapeutic product. Currently it is being evaluated in phase 2 clinical trials for the treatment of rash and skin disorders associated with EGFR inhibitor therapy.
Product Name : HT-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 27, 2023
Lead Product(s) : Aprepitant
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aprepitant
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Washington University School of Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims at activation of Washington University School of Medicine as the first clinical site in the CLEER-001 Phase 2a clinical trial of HT-001 (aprepitant) for the treatment for rash and skin disorders associated with EGFR inhibitor thera...
Product Name : HT-001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 03, 2023
Lead Product(s) : Aprepitant
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Washington University School of Medicine
Deal Size : Undisclosed
Deal Type : Collaboration